{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=I-DXd", "query": { "intervention": "I-DXd" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 35, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=I-DXd&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T09:24:06.356Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06203210", "title": "A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Ifinatamab deruxtecan", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Amrubicin", "type": "DRUG" }, { "name": "Lurbinectedin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2024-05-21", "completion_date": "2029-12-01", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-02T09:24:06.356Z", "location_count": 30, "location_summary": "Springdale, Arkansas • Fullerton, California • Los Angeles, California + 24 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06203210" }, { "nct_id": "NCT07630974", "title": "A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Neoplasm" ], "interventions": [ { "name": "Ifinatamab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Month to 17 Years" }, "enrollment_count": 134, "start_date": "2026-07-06", "completion_date": "2031-08-17", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-02T09:24:06.356Z", "location_count": 8, "location_summary": "Iowa City, Iowa • Boston, Massachusetts • New Brunswick, New Jersey + 5 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07630974" }, { "nct_id": "NCT07012031", "title": "Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Lung Non-Small Cell Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Sotorasib", "type": "DRUG" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2026-06-17", "completion_date": "2027-06-14", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-02T09:24:06.356Z", "location_count": 9, "location_summary": "Sacramento, California • Tampa, Florida • Wesley Chapel, Florida + 4 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Wesley Chapel", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07012031" }, { "nct_id": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "Metastatic Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "Zongertinib", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Trastuzumab emtansine", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "zanidatamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 768, "start_date": "2024-06-28", "completion_date": "2029-01-08", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-02T09:24:06.356Z", "location_count": 26, "location_summary": "Cerritos, California • Los Angeles, California • Orange, California + 18 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06324357" }, { "nct_id": "NCT05280470", "title": "Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive-stage Small-cell Lung Cancer" ], "interventions": [ { "name": "Ifinatamab Deruxtecan (I-DXd)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 187, "start_date": "2022-03-09", "completion_date": "2026-12-15", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-09-02T09:24:06.356Z", "location_count": 16, "location_summary": "Springdale, Arkansas • Jacksonville, Florida • Tampa, Florida + 13 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05280470" }, { "nct_id": "NCT06172127", "title": "PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection", "type": "DRUG" }, { "name": "Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedSIR", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2024-07-22", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-09-02T09:24:06.356Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06172127" }, { "nct_id": "NCT07405151", "title": "A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Oesophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "I-DXd", "type": "BIOLOGICAL" }, { "name": "Rescue Medication", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-03-27", "completion_date": "2028-06-12", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-02T09:24:06.356Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07405151" }, { "nct_id": "NCT06863272", "title": "A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Castration-Resistant Prostatic Cancer", "Metastasis" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Ifinatamab Deruxtecan", "type": "DRUG" }, { "name": "Opevesostat", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Rescue Medication", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 360, "start_date": "2025-07-03", "completion_date": "2031-04-01", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-02T09:24:06.356Z", "location_count": 9, "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06863272" }, { "nct_id": "NCT05372614", "title": "Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Solid Neoplasm", "Metastatic Pancreatic Adenocarcinoma", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Malignant Solid Neoplasm", "Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Neratinib Maleate", "type": "DRUG" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2022-10-05", "completion_date": "2028-07-17", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-02T09:24:06.356Z", "location_count": 18, "location_summary": "Duarte, California • Irvine, California • Lancaster, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05372614" }, { "nct_id": "NCT06644781", "title": "A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Ifinatamab deruxtecan", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Irinotecan hydrochloride (HCl)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 510, "start_date": "2025-03-27", "completion_date": "2029-11-01", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-09-02T09:24:06.356Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Fullerton, California • Orange, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06644781" } ] }